A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
Francesco PattiClara Grazia ChisariOscar FernándezJorge SarrocaElena Ferrer-PicónFrancisco Hernández VicenteCarlos Vila SilvánPublished in: European journal of neurology (2022)
This real-world analysis supports the concept of a spasticity-plus syndrome and suggests that nabiximols can favorably impact a range of spasticity-associated symptoms.